Gemfibrozil reduces release of tumor necrosis factor-α in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease

Clinica Chimica Acta

Volumn 332, Issue 1-2, 2003, Pages 61-67

  Zhao, Shui Ping ^a   Ye, Hui Jun ^a   Zhou, Hong Nian ^a   Nie, Sai ^a   Li, Quan Zhong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Atherosclerosis; Cytokines; Fibrates; Inflammation; TNF

Indexed keywords

ANGIOTENSIN; GEMFIBROZIL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; ISCHEMIC HEART DISEASE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; SUPERNATANT;

EID: 0037648909     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00123-2     Document Type: Article

References (36)

1. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N. Engl. J. Med. 343:2000;1139-1147.
2. Vorchheimer D.A., Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. JAMA. 286:2001;2154-2156.
3. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
4. Koukkunen H., Penttila K., Kemppainen A.et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann. Med. 33:2001;37-47.
5. Aukrust P., Berge R.K., Ueland T.et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J. Am. Coll. Cardiol. 37:2001;485-491.
6. Balbay Y., Tikiz H., Baptiste R.J., Ayaz S., Sasmaz H., Korkmaz S. Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction. Angiology. 52:2001;109-114.
7. Rus H.G., Niculescu F., Vlaicu R. Tumor necrosis factor-a in human arterial wall with atherosclerosis. Atherosclerosis. 89:1991;247-254.
8. Niemann-Jönsson A., Dimayuga P., Jovinge S.et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-a expression. Arterioscler. Thromb. Vasc. Biol. 20:2000;2205-2211.
9. Irwin M.W., Mak S., Mann D.L.et al. Tissue expression and immunolocalization of tumor necrosis factor-a in postinfarction dysfunctional myocardium. Circulation. 99:1999;1492-1498.
10. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation. 102:2000;21-27.
11. Robins S.J., Collins D., Wittes J.T.et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 285:2001;1585-1591.
12. Malik J., Melenovsky V., Wichterle D.et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate Versus Atorvastatin Trial-FAT). Cardiovasc. Res. 52:2001;290-298.
13. Marx N., Kehrle B., Kohlhammer K.et al. PPAR activators as antiinflammatory mediators in human T lymphocytes. Circ. Res. 90:2002;703-710.
14. Takano H., Nagai T., Asakawa M.et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ. Res. 87:2000;596-602.
15. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169:2001;453-459.
16. Zhao S.P., Liu L., Gao M., Zhou Q.C., Li Y.L., Xia B. Impairment of endothelial function after a high-fat meal in patients with coronary artery disease. Coron. Artery Dis. 12:2001;561-565.
17. Zhao S.P., Xie X.M. Captopril inhibits the production of tumor necrosis factor-a by human mononuclear cells in patients with congestive heart failure. Clin. Chim. Acta. 304:2001;85-90.
18. Kaul D. Molecular link between cholesterol, cytokines and atherosclerosis. Mol. Cell. Biochem. 219:2001;65-71.
19. Wertheimer S.J., Myers C.L., Wallace R.W., Parks T.P. Intercellular adhesion molecule-1 gene expression in human endothelial cells: differential regulation by TNF-α and phorbol myristate acetate. J. Biol. Chem. 267:1992;12030-12035.
20. Jovinge S., Hultgardh-Nilsson A., Regnstrom J., Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler. Thromb. Vasc. Biol. 17:1997;490-497.
21. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J. Clin. Invest. 95:1995;2409-2415.
22. Jovinge S., Ares M.P., Kallin B., Nilsson J. Human monocytes/macrophages release TNF-α in response to ox-LDL. Arterioscler. Thromb. Vasc. Biol. 16:1997;1573-1579.
23. Kalra D., Sivasubramanian N., Mann D.L. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C dependent pathway. Circulation. 105:2002;2198-2205.
24. Wagner D.R., Combes A., McTiernan C., Sanders V.J., Lemster B., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-a. Circ. Res. 82:1998;47-56.
25. Kranzhofer R., Browatzki M., Schmidt J., Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappa B in human monocytes. Biochem. Biophys. Res. Commun. 257:1999;826-828.
26. Gavras H., Brunner H.R. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension. 37:2001;342-345.
27. Dorffel Y., Latsch C., Stuhlmuller B.et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 34:1999;113-117.
28. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
29. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
30. Marx N., Sukhova G., Collins T., Libby P., Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.
31. Marx N., Schonbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1998;1097-1103.
32. Staels B., Koenig W., Habib A.et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:1998;790-793.
33. Delerive P., De Bosscher K., Besnard S.et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J. Biol. Chem. 274:1999;32048-32054.
34. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275:2000;36703-36707.
35. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K.et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168:2002;2795-2802.
36. Steiner G., Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 357:2001;905-910.